The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-Ras Mutation Status: Analysis of a Phase III Study of Bevacizumab With Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Oncologist - United States
doi 10.1634/theoncologist.2008-0213
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2009
Authors
Publisher
Alphamed Press